20 Apr 2021
Posted in Pharma
Diagnosed incident cases of melanoma in Canada projected to increase by 23.35% by 2029, says GlobalData
Diagnosed incident cases of melanoma in the eight major markets (8MM*) combined is expected to increase from 0.19 million cases in 2019 to 0.22 million cases in 2029, at an annual growth rate (AGR) of 1.66%, according to GlobalData, a leading data and analytics company.
Of the 8MM, the diagnosed incident cases of melanoma in Canada are expected to increase at an AGR of 2.34% (2019–2029), followed by the US (2.19%), and Australia (2.14%).
GlobalData’s latest report, ‘Melanoma – Epidemiology Forecast Report to 2029’, notes that the major drivers will be biological, genetic, behavioural and environmental risk factors that are associated with an increased risk of developing melanoma and an increase in the exposure to ultraviolet rays coupled with population changes.
Suneedh Manthri, Associate Project Manager of Epidemiology at GlobalData, comments: “Several studies have identified biological, genetic, behavioral and environmental risk factors that are associated with an increased risk of developing melanoma. The interaction between the nature and extent of sun exposure and skin type also appear to influence the risk of melanoma. As such, vigilant protection from the sun is highly recommended for all by leading melanoma research organizations, and especially for those in high-risk groups.”
*8MM: The US, France, Germany, Italy, Spain, the UK, Japan and urban China